Polymeric compositions are provided that include a poly(ethylene glycol), a viscoelastic polymer, and an antioxidant, where, in polymerized form, the compositions have a refractive index of about 1.30 to about 1.40. Methods of synthesizing the compositions are also provided and include the steps of heating an amount of water; adding a buffering agent to the water to form a buffer solution; mixing a poly(ethylene glycol) and a viscoelastic polymer into the buffer solution to form a reactive mixture; adding a plurality of antioxidant particles to the reactive mixture; and removing suspended gas bubbles from the reactive mixture. Methods of preventing oxidative damage to an eye lens of a subject are further provided and include administering the foregoing polymeric compositions to the eye lens of the subject.

Polymeric compositions are provided that include a poly(ethylene glycol), a viscoelastic polymer, and an antioxidant, where, in polymerized form, the compositions have a refractive index of about 1.30 to about 1.40. Methods of synthesizing the compositions are also provided and include the steps of heating an amount of water; adding a buffering agent to the water to form a buffer solution; mixing a poly(ethylene glycol) and a viscoelastic polymer into the buffer solution to form a reactive mixture; adding a plurality of antioxidant particles to the reactive mixture; and removing suspended gas bubbles from the reactive mixture. Methods of preventing oxidative damage to an eye lens of a subject are further provided and include administering the foregoing polymeric compositions to the eye lens of the subject.

Polymeric compositions are provided that include a poly(ethylene glycol), a viscoelastic polymer, and an antioxidant, where, in polymerized form, the compositions have a refractive index of about 1.30 to about 1.40. Methods of synthesizing the compositions are also provided and include the steps of heating an amount of water; adding a buffering agent to the water to form a buffer solution; mixing a poly(ethylene glycol) and a viscoelastic polymer into the buffer solution to form a reactive mixture; adding a plurality of antioxidant particles to the reactive mixture; and removing suspended gas bubbles from the reactive mixture. Methods of preventing oxidative damage to an eye lens of a subject are further provided and include administering the foregoing polymeric compositions to the eye lens of the subject.

Compositions are provided herein comprising a coacervate of a polycationic polymer, a polyanionic polymer, and platelet-rich plasma and/or serum, or a fraction or concentrate thereof. The composition is useful in wound healing. Compositions also are provided that comprise a hydrogel comprising TIMP-3; and a complex of a polycationic polymer, a polyanionic polymer, FGF-2 and SDF-1α embedded in the hydrogel, which is useful in treating a myocardial infarction.

Compositions are provided herein comprising a coacervate of a polycationic polymer, a polyanionic polymer, and platelet-rich plasma and/or serum, or a fraction or concentrate thereof. The composition is useful in wound healing. Compositions also are provided that comprise a hydrogel comprising TIMP-3; and a complex of a polycationic polymer, a polyanionic polymer, FGF-2 and SDF-1α embedded in the hydrogel, which is useful in treating a myocardial infarction.

The present invention aims to provide a method for producing a porous substrate containing a bioabsorbable polymer and heparin in a simple manner without use of a surfactant, a porous substrate containing a bioabsorbable polymer and heparin, and an artificial blood vessel. The present invention provides a method for producing a porous substrate containing a bioabsorbable polymer and heparin, including: a solution preparing step of preparing a heparin-bioabsorbable polymer solution having heparin uniformly dispersed therein and a bioabsorbable polymer dissolved therein, using the bioabsorbable polymer, the heparin, a solvent 1 that is a poor solvent having a lower solvency for the bioabsorbable polymer, a solvent 2 that is a good solvent having a higher solvency for the bioabsorbable polymer and is incompatible with the solvent 1, and a common solvent 3 compatible with the solvent 1 and the solvent 2; a precipitating step of cooling the heparin-bioabsorbable polymer solution to precipitate a porous body containing the bioabsorbable polymer and the heparin; and a freeze-drying step of freeze-drying the porous body containing the bioabsorbable polymer and the heparin to provide a porous substrate containing the heparin.

The present invention aims to provide a method for producing a porous substrate containing a bioabsorbable polymer and heparin in a simple manner without use of a surfactant, a porous substrate containing a bioabsorbable polymer and heparin, and an artificial blood vessel. The present invention provides a method for producing a porous substrate containing a bioabsorbable polymer and heparin, including: a solution preparing step of preparing a heparin-bioabsorbable polymer solution having heparin uniformly dispersed therein and a bioabsorbable polymer dissolved therein, using the bioabsorbable polymer, the heparin, a solvent 1 that is a poor solvent having a lower solvency for the bioabsorbable polymer, a solvent 2 that is a good solvent having a higher solvency for the bioabsorbable polymer and is incompatible with the solvent 1, and a common solvent 3 compatible with the solvent 1 and the solvent 2; a precipitating step of cooling the heparin-bioabsorbable polymer solution to precipitate a porous body containing the bioabsorbable polymer and the heparin; and a freeze-drying step of freeze-drying the porous body containing the bioabsorbable polymer and the heparin to provide a porous substrate containing the heparin.

Method for obtaining low molecular weight heparins (LMWH) with a weight average molecular weight distribution between 3.0 and 5.0 kDa comprising at least one concentration step by tangential flow filtration (TFF). The method is particularly useful for the preparation of bemiparin and enoxaparin without the use of fractional precipitation nor the use of alcoholic solutions. In particular, the preparation of LMWH is obtained by depolymerization of heparin and filtration (TFF ultrafiltration and/or diafiltration) of the depolymerized heparin without the use of fractional precipitation and without an alcoholic solution.

The present invention relates to preparation method for the scale up production of a safe bovine heparin composed by a distinctively selected unfractioned bovine heparin polymers with low 6-O-desulfated glucosamine content and a porcine-like antico-agulant activity and protamine neutralization, and methods of its production and application. This safe bovine heparin (SB Heparin) has a comparable structure and function to the porcine heparin, the clinical usage reference, preventing clinical usage impairments as a safe pharmaceutical product, allowing its use as interchangeably drugs.

A rapid testing mechanism for respiratory viral pathogens includes a filter material positioned to capture exhaled breath particles from a respiratory tract. A portion of the filter material is impregnated with a pathogen binding adsorptive reagent. When the exhaled breath particles pass through the filter material the following occurs: when the binding adsorptive reagent reacts, a positive test for respiratory viral pathogens is indicated by the filter material; and when pathogen binding adsorptive reagent does not react, a negative test for respiratory viral pathogens is indicated by the filter material.